APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Immuno-Oncology

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.

Selected research

Market Analysis & Forecast

Global Immuno-Oncology Market Analysis and Forecast 2026-2032

Report ID 173894490227 December 2025194 pages

Choose your research edition.

Industry ResearchImmuno-Oncology Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Immuno-Oncology Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Immuno-Oncology Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032184 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immuno-Oncology Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Immuno-Oncology Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.

The industry's leading producers are Bristol-Myers Squibb, Merck & Co and Roche AG, with revenues of 27.89%, 22.10% and 20.85%, respectively, in 2019.

Report Includes

Read the full market overview

This report presents an overview of global market for Immuno-Oncology, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Immuno-Oncology, also provides the revenue of main regions and countries. Of the upcoming market potential for Immuno-Oncology, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Immuno-Oncology revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Immuno-Oncology market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Immuno-Oncology revenue, projected growth trends, production technology, application and end-user industry.

Immuno-Oncology Segment by Company

Bristol-Myers Squibb

Merck & Co., Inc.

Roche AG

AstraZeneca, Plc

Sanofi S.A.

Dendreon Pharmaceuticals

Novartis

Gilead Sciences Inc.

Merck KGaA

Immuno-Oncology Segment by Type

Immune Checkpoint Inhibitors

Cytokine-Based Immunotherapy

Cancer Vaccines

CAR-T Cell Therapy

Others

Immuno-Oncology Segment by Application

Hospitals

Drugstores

Others

Immuno-Oncology Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-Oncology market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immuno-Oncology and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-Oncology.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Immuno-Oncology in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Immuno-Oncology company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immuno-Oncology revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Immuno-Oncology Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Immune Checkpoint Inhibitors Major Player Table 3. Cytokine-Based Immunotherapy Major Player Table 4. Cancer Vaccines Major Player Table 5. CAR-T Cell Therapy Major Player Table 6. Others Major Player Table 7. Global Immuno-Oncology Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 8. Hospitals Major Player Table 9. Drugstores Major Player Table 10. Others Major Player Table 11. Immuno-Oncology Industry Trends Table 12. Immuno-Oncology Industry Drivers Table 13. Immuno-Oncology Industry Opportunities and Challenges Table 14. Immuno-Oncology Industry Restraints Table 15. Global Immuno-Oncology Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Immuno-Oncology Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Immuno-Oncology Market Share by Region (2021-2026) Table 18. Global Immuno-Oncology Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Immuno-Oncology Market Share by Region (2027-2032) Table 20. Global Immuno-Oncology Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Immuno-Oncology Revenue Market Share by Players (2021-2026) Table 22. Global Immuno-Oncology Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Immuno-Oncology Key Players Headquarters & Area Served Table 24. Global Immuno-Oncology Players, Product Type & Application Table 25. Global Immuno-Oncology Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Immuno-Oncology by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Immuno-Oncology Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Immuno-Oncology Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Immuno-Oncology Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Immuno-Oncology Revenue Market Share by Type (2021-2026) Table 32. Global Immuno-Oncology Revenue Market Share by Type (2027-2032) Table 33. Global Immuno-Oncology Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Immuno-Oncology Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Immuno-Oncology Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Immuno-Oncology Revenue Market Share by Application (2021-2026) Table 37. Global Immuno-Oncology Revenue Market Share by Application (2027-2032) Table 38. Bristol-Myers Squibb Company Information Table 39. Bristol-Myers Squibb Business Overview Table 40. Bristol-Myers Squibb Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Bristol-Myers Squibb Immuno-Oncology Product Portfolio Table 42. Bristol-Myers Squibb Recent Development Table 43. Merck & Co., Inc. Company Information Table 44. Merck & Co., Inc. Business Overview Table 45. Merck & Co., Inc. Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Merck & Co., Inc. Immuno-Oncology Product Portfolio Table 47. Merck & Co., Inc. Recent Development Table 48. Roche AG Company Information Table 49. Roche AG Business Overview Table 50. Roche AG Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Roche AG Immuno-Oncology Product Portfolio Table 52. Roche AG Recent Development Table 53. AstraZeneca, Plc Company Information Table 54. AstraZeneca, Plc Business Overview Table 55. AstraZeneca, Plc Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. AstraZeneca, Plc Immuno-Oncology Product Portfolio Table 57. AstraZeneca, Plc Recent Development Table 58. Sanofi S.A. Company Information Table 59. Sanofi S.A. Business Overview Table 60. Sanofi S.A. Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Sanofi S.A. Immuno-Oncology Product Portfolio Table 62. Sanofi S.A. Recent Development Table 63. Dendreon Pharmaceuticals Company Information Table 64. Dendreon Pharmaceuticals Business Overview Table 65. Dendreon Pharmaceuticals Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Dendreon Pharmaceuticals Immuno-Oncology Product Portfolio Table 67. Dendreon Pharmaceuticals Recent Development Table 68. Novartis Company Information Table 69. Novartis Business Overview Table 70. Novartis Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Novartis Immuno-Oncology Product Portfolio Table 72. Novartis Recent Development Table 73. Gilead Sciences Inc. Company Information Table 74. Gilead Sciences Inc. Business Overview Table 75. Gilead Sciences Inc. Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Gilead Sciences Inc. Immuno-Oncology Product Portfolio Table 77. Gilead Sciences Inc. Recent Development Table 78. Merck KGaA Company Information Table 79. Merck KGaA Business Overview Table 80. Merck KGaA Immuno-Oncology Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Merck KGaA Immuno-Oncology Product Portfolio Table 82. Merck KGaA Recent Development Table 83. North America Immuno-Oncology Revenue by Type (2021-2026) & (US$ Million) Table 84. North America Immuno-Oncology Revenue by Type (2027-2032) & (US$ Million) Table 85. North America Immuno-Oncology Revenue by Application (2021-2026) & (US$ Million) Table 86. North America Immuno-Oncology Revenue by Application (2027-2032) & (US$ Million) Table 87. North America Immuno-Oncology Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. North America Immuno-Oncology Revenue by Country (2021-2026) & (US$ Million) Table 89. North America Immuno-Oncology Revenue by Country (US$ Million) & (2027-2032) Table 90. Europe Immuno-Oncology Revenue by Type (2021-2026) & (US$ Million) Table 91. Europe Immuno-Oncology Revenue by Type (2027-2032) & (US$ Million) Table 92. Europe Immuno-Oncology Revenue by Application (2021-2026) & (US$ Million) Table 93. Europe Immuno-Oncology Revenue by Application (2027-2032) & (US$ Million) Table 94. Europe Immuno-Oncology Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 95. Europe Immuno-Oncology Revenue by Country (2021-2026) & (US$ Million) Table 96. Europe Immuno-Oncology Revenue by Country (US$ Million) & (2027-2032) Table 97. China Immuno-Oncology Revenue by Type (2021-2026) & (US$ Million) Table 98. China Immuno-Oncology Revenue by Type (2027-2032) & (US$ Million) Table 99. China Immuno-Oncology Revenue by Application (2021-2026) & (US$ Million) Table 100. China Immuno-Oncology Revenue by Application (2027-2032) & (US$ Million) Table 101. Asia Immuno-Oncology Revenue by Type (2021-2026) & (US$ Million) Table 102. Asia Immuno-Oncology Revenue by Type (2027-2032) & (US$ Million) Table 103. Asia Immuno-Oncology Revenue by Application (2021-2026) & (US$ Million) Table 104. Asia Immuno-Oncology Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia Immuno-Oncology Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 106. Asia Immuno-Oncology Revenue by Region (US$ Million) & (2021-2026) Table 107. Asia Immuno-Oncology Revenue by Region (US$ Million) & (2027-2032) Table 108. SAMEA Immuno-Oncology Revenue by Type (2021-2026) & (US$ Million) Table 109. SAMEA Immuno-Oncology Revenue by Type (2027-2032) & (US$ Million) Table 110. SAMEA Immuno-Oncology Revenue by Application (2021-2026) & (US$ Million) Table 111. SAMEA Immuno-Oncology Revenue by Application (2027-2032) & (US$ Million) Table 112. SAMEA Immuno-Oncology Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 113. SAMEA Immuno-Oncology Revenue by Country (2021-2026) & (US$ Million) Table 114. SAMEA Immuno-Oncology Revenue by Country (US$ Million) & (2027-2032) Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Immuno-Oncology Image Figure 2. Global Immuno-Oncology Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Immuno-Oncology Market Size Share 2021 VS 2025 VS 2032 Figure 4. Immune Checkpoint Inhibitors Image Figure 5. Cytokine-Based Immunotherapy Image Figure 6. Cancer Vaccines Image Figure 7. CAR-T Cell Therapy Image Figure 8. Others Image Figure 9. Global Immuno-Oncology Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Immuno-Oncology Market Size Share 2021 VS 2025 VS 2032 Figure 11. Hospitals Image Figure 12. Drugstores Image Figure 13. Others Image Figure 14. Global Immuno-Oncology Market Size (US$ Million) & (2021-2032) Figure 15. Global Immuno-Oncology Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Immuno-Oncology Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Immuno-Oncology Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Immuno-Oncology Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Immuno-Oncology Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Immuno-Oncology Revenue Market Share by Type (2021-2032) Figure 22. Global Immuno-Oncology Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Immuno-Oncology Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Immuno-Oncology Revenue Market Share by Application (2021-2032) Figure 25. North America Immuno-Oncology Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Immuno-Oncology Revenue Share by Type (2021-2032) Figure 27. North America Immuno-Oncology Revenue Share by Application (2021-2032) Figure 28. North America Immuno-Oncology Revenue Share by Country (2021-2032) Figure 29. United States Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Immuno-Oncology Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Immuno-Oncology Revenue Share by Type (2021-2032) Figure 34. Europe Immuno-Oncology Revenue Share by Application (2021-2032) Figure 35. Europe Immuno-Oncology Revenue Share by Country (2021-2032) Figure 36. Germany Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Immuno-Oncology Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Immuno-Oncology Revenue Share by Type (2021-2032) Figure 46. China Immuno-Oncology Revenue Share by Application (2021-2032) Figure 47. Asia Immuno-Oncology Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Immuno-Oncology Revenue Share by Type (2021-2032) Figure 49. Asia Immuno-Oncology Revenue Share by Application (2021-2032) Figure 50. Asia Immuno-Oncology Revenue Share by Region (2021-2032) Figure 51. Japan Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Immuno-Oncology Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Immuno-Oncology Revenue Share by Type (2021-2032) Figure 59. SAMEA Immuno-Oncology Revenue Share by Application (2021-2032) Figure 60. SAMEA Immuno-Oncology Revenue Share by Country (2021-2032) Figure 61. Brazil Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Immuno-Oncology Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Immune Checkpoint Inhibitors
  • Cytokine-Based Immunotherapy
  • Cancer Vaccines
  • CAR-T Cell Therapy
  • Others
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Roche AG
  • AstraZeneca, Plc
  • Sanofi S.A.
  • Dendreon Pharmaceuticals
  • Novartis
  • Gilead Sciences Inc.
  • Merck KGaA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Immuno-Oncology Market by Type
  3. 1.2.1 Global Immuno-Oncology Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Immune Checkpoint Inhibitors
  5. 1.2.3 Cytokine-Based Immunotherapy
  6. 1.2.4 Cancer Vaccines
  7. 1.2.5 CAR-T Cell Therapy
  8. 1.2.6 Others
  9. 1.3 Immuno-Oncology Market by Application
  10. 1.3.1 Global Immuno-Oncology Market Size by Application, 2021 VS 2025 VS 2032
  11. 1.3.2 Hospitals
  12. 1.3.3 Drugstores
  13. 1.3.4 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Immuno-Oncology Market Dynamics
  1. 2.1 Immuno-Oncology Industry Trends
  2. 2.2 Immuno-Oncology Industry Drivers
  3. 2.3 Immuno-Oncology Industry Opportunities and Challenges
  4. 2.4 Immuno-Oncology Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Immuno-Oncology Market Perspective (2021-2032)
  2. 3.2 Global Immuno-Oncology Growth Trends by Region
  3. 3.2.1 Global Immuno-Oncology Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Immuno-Oncology Market Size by Region (2021-2026)
  5. 3.2.3 Global Immuno-Oncology Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Immuno-Oncology Revenue by Players
  2. 4.1.1 Global Immuno-Oncology Revenue by Players (2021-2026)
  3. 4.1.2 Global Immuno-Oncology Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Immuno-Oncology Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Immuno-Oncology Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Immuno-Oncology Key Players Headquarters & Area Served
  7. 4.4 Global Immuno-Oncology Players, Product Type & Application
  8. 4.5 Global Immuno-Oncology Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Immuno-Oncology Market CR5 and HHI
  11. 4.6.3 2025 Immuno-Oncology Tier 1, Tier 2, and Tier 3
5 Immuno-Oncology Market Size by Type
  1. 5.1 Global Immuno-Oncology Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Immuno-Oncology Revenue by Type (2021-2032)
  3. 5.3 Global Immuno-Oncology Revenue Market Share by Type (2021-2032)
6 Immuno-Oncology Market Size by Application
  1. 6.1 Global Immuno-Oncology Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Immuno-Oncology Revenue by Application (2021-2032)
  3. 6.3 Global Immuno-Oncology Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bristol-Myers Squibb
  2. 7.1.1 Bristol-Myers Squibb Company Information
  3. 7.1.2 Bristol-Myers Squibb Business Overview
  4. 7.1.3 Bristol-Myers Squibb Immuno-Oncology Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bristol-Myers Squibb Immuno-Oncology Product Portfolio
  6. 7.1.5 Bristol-Myers Squibb Recent Developments
  7. 7.2 Merck & Co., Inc.
  8. 7.2.1 Merck & Co., Inc. Company Information
  9. 7.2.2 Merck & Co., Inc. Business Overview
  10. 7.2.3 Merck & Co., Inc. Immuno-Oncology Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Merck & Co., Inc. Immuno-Oncology Product Portfolio
  12. 7.2.5 Merck & Co., Inc. Recent Developments
  13. 7.3 Roche AG
  14. 7.3.1 Roche AG Company Information
  15. 7.3.2 Roche AG Business Overview
  16. 7.3.3 Roche AG Immuno-Oncology Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Roche AG Immuno-Oncology Product Portfolio
  18. 7.3.5 Roche AG Recent Developments
  19. 7.4 AstraZeneca, Plc
  20. 7.4.1 AstraZeneca, Plc Company Information
  21. 7.4.2 AstraZeneca, Plc Business Overview
  22. 7.4.3 AstraZeneca, Plc Immuno-Oncology Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AstraZeneca, Plc Immuno-Oncology Product Portfolio
  24. 7.4.5 AstraZeneca, Plc Recent Developments
  25. 7.5 Sanofi S.A.
  26. 7.5.1 Sanofi S.A. Company Information
  27. 7.5.2 Sanofi S.A. Business Overview
  28. 7.5.3 Sanofi S.A. Immuno-Oncology Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sanofi S.A. Immuno-Oncology Product Portfolio
  30. 7.5.5 Sanofi S.A. Recent Developments
  31. 7.6 Dendreon Pharmaceuticals
  32. 7.6.1 Dendreon Pharmaceuticals Company Information
  33. 7.6.2 Dendreon Pharmaceuticals Business Overview
  34. 7.6.3 Dendreon Pharmaceuticals Immuno-Oncology Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Dendreon Pharmaceuticals Immuno-Oncology Product Portfolio
  36. 7.6.5 Dendreon Pharmaceuticals Recent Developments
  37. 7.7 Novartis
  38. 7.7.1 Novartis Company Information
  39. 7.7.2 Novartis Business Overview
  40. 7.7.3 Novartis Immuno-Oncology Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Novartis Immuno-Oncology Product Portfolio
  42. 7.7.5 Novartis Recent Developments
  43. 7.8 Gilead Sciences Inc.
  44. 7.8.1 Gilead Sciences Inc. Company Information
  45. 7.8.2 Gilead Sciences Inc. Business Overview
  46. 7.8.3 Gilead Sciences Inc. Immuno-Oncology Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Gilead Sciences Inc. Immuno-Oncology Product Portfolio
  48. 7.8.5 Gilead Sciences Inc. Recent Developments
  49. 7.9 Merck KGaA
  50. 7.9.1 Merck KGaA Company Information
  51. 7.9.2 Merck KGaA Business Overview
  52. 7.9.3 Merck KGaA Immuno-Oncology Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Merck KGaA Immuno-Oncology Product Portfolio
  54. 7.9.5 Merck KGaA Recent Developments
8 North America
  1. 8.1 North America Immuno-Oncology Revenue (2021-2032)
  2. 8.2 North America Immuno-Oncology Revenue by Type (2021-2032)
  3. 8.2.1 North America Immuno-Oncology Revenue by Type (2021-2026)
  4. 8.2.2 North America Immuno-Oncology Revenue by Type (2027-2032)
  5. 8.3 North America Immuno-Oncology Revenue Share by Type (2021-2032)
  6. 8.4 North America Immuno-Oncology Revenue by Application (2021-2032)
  7. 8.4.1 North America Immuno-Oncology Revenue by Application (2021-2026)
  8. 8.4.2 North America Immuno-Oncology Revenue by Application (2027-2032)
  9. 8.5 North America Immuno-Oncology Revenue Share by Application (2021-2032)
  10. 8.6 North America Immuno-Oncology Revenue by Country
  11. 8.6.1 North America Immuno-Oncology Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Immuno-Oncology Revenue by Country (2021-2026)
  13. 8.6.3 North America Immuno-Oncology Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Immuno-Oncology Revenue (2021-2032)
  2. 9.2 Europe Immuno-Oncology Revenue by Type (2021-2032)
  3. 9.2.1 Europe Immuno-Oncology Revenue by Type (2021-2026)
  4. 9.2.2 Europe Immuno-Oncology Revenue by Type (2027-2032)
  5. 9.3 Europe Immuno-Oncology Revenue Share by Type (2021-2032)
  6. 9.4 Europe Immuno-Oncology Revenue by Application (2021-2032)
  7. 9.4.1 Europe Immuno-Oncology Revenue by Application (2021-2026)
  8. 9.4.2 Europe Immuno-Oncology Revenue by Application (2027-2032)
  9. 9.5 Europe Immuno-Oncology Revenue Share by Application (2021-2032)
  10. 9.6 Europe Immuno-Oncology Revenue by Country
  11. 9.6.1 Europe Immuno-Oncology Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Immuno-Oncology Revenue by Country (2021-2026)
  13. 9.6.3 Europe Immuno-Oncology Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Immuno-Oncology Revenue (2021-2032)
  2. 10.2 China Immuno-Oncology Revenue by Type (2021-2032)
  3. 10.2.1 China Immuno-Oncology Revenue by Type (2021-2026)
  4. 10.2.2 China Immuno-Oncology Revenue by Type (2027-2032)
  5. 10.3 China Immuno-Oncology Revenue Share by Type (2021-2032)
  6. 10.4 China Immuno-Oncology Revenue by Application (2021-2032)
  7. 10.4.1 China Immuno-Oncology Revenue by Application (2021-2026)
  8. 10.4.2 China Immuno-Oncology Revenue by Application (2027-2032)
  9. 10.5 China Immuno-Oncology Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Immuno-Oncology Revenue (2021-2032)
  2. 11.2 Asia Immuno-Oncology Revenue by Type (2021-2032)
  3. 11.2.1 Asia Immuno-Oncology Revenue by Type (2021-2026)
  4. 11.2.2 Asia Immuno-Oncology Revenue by Type (2027-2032)
  5. 11.3 Asia Immuno-Oncology Revenue Share by Type (2021-2032)
  6. 11.4 Asia Immuno-Oncology Revenue by Application (2021-2032)
  7. 11.4.1 Asia Immuno-Oncology Revenue by Application (2021-2026)
  8. 11.4.2 Asia Immuno-Oncology Revenue by Application (2027-2032)
  9. 11.5 Asia Immuno-Oncology Revenue Share by Application (2021-2032)
  10. 11.6 Asia Immuno-Oncology Revenue by Country
  11. 11.6.1 Asia Immuno-Oncology Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Immuno-Oncology Revenue by Country (2021-2026)
  13. 11.6.3 Asia Immuno-Oncology Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Immuno-Oncology Revenue (2021-2032)
  2. 12.2 SAMEA Immuno-Oncology Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Immuno-Oncology Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Immuno-Oncology Revenue by Type (2027-2032)
  5. 12.3 SAMEA Immuno-Oncology Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Immuno-Oncology Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Immuno-Oncology Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Immuno-Oncology Revenue by Application (2027-2032)
  9. 12.5 SAMEA Immuno-Oncology Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Immuno-Oncology Revenue by Country
  11. 12.6.1 SAMEA Immuno-Oncology Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Immuno-Oncology Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Immuno-Oncology Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst